Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized feasibility study of weekly versus every-3-week docetaxel plus prednisone in vulnerable or frail patients aged 75 years or older with progressive metastatic castration-resistant prostate adenocarcinoma
2009-017092-24Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and prednisone in prostate cancer (PCa) and prostate adenocarcinoma (2 arms), sponsored by Unicancer. Started Jul 2010; status: completed.
02
Drugs
docetaxelprednisone
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on 2009-017092-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017092-24.